At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 40 target
Drug / intervention
SHR6390drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma
In Brief
A Phase 1 clinical trial evaluating SHR6390 for Gastric Cancer. Targeting 40 participants across 2 sites.
Detailed Summary
The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesChina
CollaboratorsJiangsu HengRui Medicine Co., Ltd.
Timeline
Phase 1UnknownOverdue
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartJul 2018
Primary CompletionNov 2019
Study CompletionAug 2020
TodayJul 2026
First PostedMar 29, 2018
Enrollment StartJul 27, 2018
Primary CompletionNov 1, 2019
Study CompletionAug 1, 2020
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 8.3 years ago
Interventions
SHR6390drug
SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer